Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert I Nicholson

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Expert Review of Endocrinology & Metabolism|February 14, 2019
Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancerStephen Hiscox, Robert I Nicholson
Expert Opinion on Therapeutic Targets|May 16, 2008
Src inhibitors in breast cancer therapyStephen Hiscox, Robert I Nicholson
Breast Cancer Research and Treatment|October 26, 2005
Endocrine therapy--current benefits and limitationsRobert I Nicholson, Stephen R Johnston
Biochimica Et Biophysica Acta|March 28, 2003
The LZT proteins; the LIV-1 subfamily of zinc transportersKathryn M Taylor, Robert I Nicholson
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Acquired endocrine resistance in breast cancer: implications for tumour metastasisEdd Hayes, Robert I Nicholson, Stephen Hiscox
Endocrine, Metabolic & Immune Disorders Drug Targets|December 17, 2008
SRC as a therapeutic target in breast cancerLiam Morgan, Robert I Nicholson, Stephen Hiscox
Breast Cancer Research : BCR|June 10, 2003
Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitizationJulia M W Gee, Robert I Nicholson
Expert Opinion on Therapeutic Targets|March 11, 2011
Therapeutic targeting of tumor-stroma interactionsStephen Hiscox, Peter Barrett-Lee, Robert I Nicholson
Breast Cancer Research and Treatment|October 26, 2005
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistanceMitch Dowsett, Robert I Nicholson, Richard J Pietras
Endocrine-Related Cancer|January 30, 2007
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancerStephen Hiscox, L Morgan, Tim Green, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Expert Review of Endocrinology & Metabolism|February 14, 2019
Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancerStephen Hiscox, Robert I Nicholson
Expert Opinion on Therapeutic Targets|May 16, 2008
Src inhibitors in breast cancer therapyStephen Hiscox, Robert I Nicholson
Breast Cancer Research and Treatment|October 26, 2005
Endocrine therapy--current benefits and limitationsRobert I Nicholson, Stephen R Johnston
Biochimica Et Biophysica Acta|March 28, 2003
The LZT proteins; the LIV-1 subfamily of zinc transportersKathryn M Taylor, Robert I Nicholson
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Acquired endocrine resistance in breast cancer: implications for tumour metastasisEdd Hayes, Robert I Nicholson, Stephen Hiscox
Endocrine, Metabolic & Immune Disorders Drug Targets|December 17, 2008
SRC as a therapeutic target in breast cancerLiam Morgan, Robert I Nicholson, Stephen Hiscox
Breast Cancer Research : BCR|June 10, 2003
Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitizationJulia M W Gee, Robert I Nicholson
Expert Opinion on Therapeutic Targets|March 11, 2011
Therapeutic targeting of tumor-stroma interactionsStephen Hiscox, Peter Barrett-Lee, Robert I Nicholson
Breast Cancer Research and Treatment|October 26, 2005
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistanceMitch Dowsett, Robert I Nicholson, Richard J Pietras
Endocrine-Related Cancer|January 30, 2007
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancerStephen Hiscox, L Morgan, Tim Green, et al.
Pageof 8